Table 2.
Initial study (n = 19) | FU study (n = 19) | P-valuea | |
---|---|---|---|
CAV area (5 mm) | |||
Average lumen area (mm2) | 10.3 ± 2.9 | 9.4 ± 3.6 | 0.133 |
Average vessel area (mm2) | 13.3 ± 3.1 | 13.4 ± 3.9 | 0.852 |
Average vessel volume (mm3) | 66.7 ± 15.1 | 67.1 ± 19.5 | 0.852 |
Plaque volume (mm3) | 15.4 ± 3.9 | 20.8 ± 6.5 | <0.001 |
Per cent plaque volume (%) | 23.9 ± 7.1 | 32.8 ± 11.2 | <0.001 |
Vasa vasorum area (5 mm) | |||
Average lumen area (mm2) | 9.9 ± 2.5 | 9.2 ± 3.4 | 0.215 |
Average vessel area (mm2) | 11.9 ± 2.7 | 11.8 ± 3.6 | 0.859 |
Average vessel volume (mm3) | 59.5 ± 13.5 | 59.0 ± 18.1 | 0.859 |
Plaque volume (mm3) | 10.1 ± 2.8 | 12.8 ± 3.4 | <0.001 |
Per cent plaque volume (%)b | 17.4 ± 5.0 | 23.2 ± 7.6 | <0.001 |
CAV, cardiac allograft vasculopathy; FU, follow-up.
aAll P-values are from the Wilcoxon singed rank test.
b(Plaque volume/average vessel volume) × 100.